Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease
- PMID: 20030475
- DOI: 10.1592/phco.30.1.70
Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease
Abstract
Ferumoxytol is an intravenous iron preparation for treatment of the anemia of chronic kidney disease (CKD). It is a carbohydrate-coated, superparamagnetic iron oxide nanoparticle. Because little free iron is present in the preparation, doses of 510 mg have been administered safely in as little as 17 seconds. Two prospective, randomized studies compared two doses of ferumoxytol 510 mg given in 5 +/- 3 days with 3 weeks of oral iron 200 mg/day (as ferrous fumarate) in anemic patients with CKD. One study enrolled 304 patients with stages 1-5 CKD (predialysis), and the other study enrolled 230 patients with stage 5D CKD (undergoing hemodialysis). In both studies, a greater increase in hemoglobin level from baseline to end of study (day 35) was noted in patients who received ferumoxytol compared with those who received oral iron (mean +/- SD 0.82 +/- 1.24 vs 0.16 +/- 1.02 g/dl in patients with stages 1-5 CKD and 1.02 +/- 1.13 vs 0.46 +/- 1.06 g/dl in patients with stage 5D CKD, p<0.001). A greater proportion of both predialysis and hemodialysis patients who received ferumoxytol had hemoglobin level increases from baseline of 1 g/dl or more compared with those who received oral iron (p<0.001). In a prospective, double-blind, crossover study of more than 700 patients with CKD stages 1-5D that compared the safety of ferumoxytol with normal saline injection, the rates of treatment-related adverse events were 5.2% and 4.5%, respectively. Serious treatment-related adverse events were seen in one patient in each treatment group. The most common adverse events with ferumoxytol occurred at the injection site (bruising, pain, swelling, erythema). Dizziness, nausea, pruritus, headache, and fatigue occurred in less than 2% of patients receiving ferumoxytol, with a similar frequency noted after administration of normal saline. In short-term studies, intravenous ferumoxytol was safely and rapidly administered, and was more effective than oral iron therapy in increasing hemoglobin levels in anemic patients with CKD. Long-term clinical trials with clinical outcomes and studies comparing ferumoxytol with other parenteral iron agents will help define the role of ferumoxytol in treating the anemia of CKD.
Similar articles
-
Safety of ferumoxytol in patients with anemia and CKD.Am J Kidney Dis. 2008 Nov;52(5):907-15. doi: 10.1053/j.ajkd.2008.08.001. Epub 2008 Sep 27. Am J Kidney Dis. 2008. PMID: 18824288 Clinical Trial.
-
Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period.Clin Ther. 2014 Jan 1;36(1):70-83. doi: 10.1016/j.clinthera.2013.09.028. Epub 2013 Dec 7. Clin Ther. 2014. PMID: 24315802
-
A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.Clin J Am Soc Nephrol. 2014 Apr;9(4):705-12. doi: 10.2215/CJN.05320513. Epub 2014 Jan 23. Clin J Am Soc Nephrol. 2014. PMID: 24458078 Free PMC article. Clinical Trial.
-
Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease.J Nephrol. 2011 Nov-Dec;24(6):717-22. doi: 10.5301/jn.5000025. J Nephrol. 2011. PMID: 21956770 Review.
-
Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease.Expert Opin Pharmacother. 2009 Oct;10(15):2563-8. doi: 10.1517/14656560903224998. Expert Opin Pharmacother. 2009. PMID: 19708851 Review.
Cited by
-
Ex Vivo and In Vivo Evaluation of Dodecaborate-Based Clusters Encapsulated in Ferumoxytol Nanoparticles.Langmuir. 2021 Dec 14;37(49):14500-14508. doi: 10.1021/acs.langmuir.1c02506. Epub 2021 Nov 29. Langmuir. 2021. PMID: 34843246 Free PMC article.
-
Iron oxide nanoparticles trigger endoplasmic reticulum damage in steatotic hepatic cells.Nanoscale Adv. 2023 Jul 18;5(16):4250-4268. doi: 10.1039/d3na00071k. eCollection 2023 Aug 8. Nanoscale Adv. 2023. PMID: 37560414 Free PMC article.
-
SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI.Neoplasia. 2017 Jan;19(1):1-7. doi: 10.1016/j.neo.2016.11.010. Epub 2016 Dec 7. Neoplasia. 2017. PMID: 27940247 Free PMC article.
-
Topical ferumoxytol nanoparticles disrupt biofilms and prevent tooth decay in vivo via intrinsic catalytic activity.Nat Commun. 2018 Jul 31;9(1):2920. doi: 10.1038/s41467-018-05342-x. Nat Commun. 2018. PMID: 30065293 Free PMC article.
-
In Vivo Tracking of Tissue Engineered Constructs.Micromachines (Basel). 2019 Jul 16;10(7):474. doi: 10.3390/mi10070474. Micromachines (Basel). 2019. PMID: 31315207 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical